阿托伐他汀钙对冠心病合并射血分数降低的心力衰竭患者血清hs-CRP水平及心功能的影响

Effect of atorvastatin calcium on serum hs-CRP level and cardiac function in patients with coronary heart disease and heart failure with reduced ejection fraction

目的观察阿托伐他汀钙对冠心病合并射血分数降低的心力衰竭患者血清超敏C-反应蛋白(hs-CRP)水平及心功能的影响。方法选取2018年2月至2019年1月80例冠心病合并射血分数降低的心力衰竭患者为研究对象,分为对照组与观察组,每组40例。对照组采取常规治疗方案;观察组在对照组治疗基础上给予阿托伐他汀钙治疗。比较两组血清hs-CRP、B型利钠肽(BNP)水平、左室射血分数(LVEF)、6 min步行距离、不良心血管事件(MACE)发生率及不良反应发生率。结果治疗后,观察组患者的血清hs-CRP、B型利钠肽(BNP)水平均明显低于对照组,左室射血分数(LVEF)、6 min步行距离均明显高于对照组,且不良心血管事件(MACE)发生率低于对照组(P<0.05)。两组患者不良反应发生率比较差异未见统计学意义(P>0.05)。结论对冠心病合并射血分数降低的心力衰竭患者应用阿托伐他汀钙辅助治疗可减轻机体炎性反应,改善患者心功能,减少MACE发生。

Objective To observe the effects of atorvastatin calcium on serum high-sensitivity C-reactive protein(hs-CRP) level and cardiac function in patients with coronary heart disease and heart failure with decreased ejection fraction. Methods Eighty patients with heart failure with low ejection fraction and coronary heart disease from February 2018 to January 2019 were selected as the objects of study. They were divided into control group and observation group, with 40 cases in each group.The control group received routine treatment.The observation group was treated with altovastatin calcium on the basis of the control group.The levels of hs-CRP, B-type natriuretic peptide(BNP), left ventricular ejection fraction(LVEF), 6 min walking distance, adverse cardiovascular events(MACE) and adverse reactions were compared between the two groups. Results After treatment, the serum levels of hs-CRP and BNP in the observation group were lower than those in the control group, the left ventricular ejection fraction(LVEF) and 6-minute walking distance were significantly higher than those in the control group, the incidence of adverse cardiovascular events(MACE) was lower than that of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions The application of atorvastatin calcium adjuvant therapy to patients with heart failure with coronary heart disease with reduced ejection score can reduce the inflammatory response of the body, improve the cardiac function of the patients, and reduce the occurrence of MACE.